Actively Recruiting
Phase I Study of Papaverine With Chemoradiation to Treat Stage II-III Non-Small Cell Lung Cancer
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-06-30
28
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying papaverine in combination with chemoradiation to find the best dose and assess possible benefits and side effects for patients with stage II-III non-small cell lung cancer that cannot be surgically removed or has limited metastases. Papaverine targets mitochondrial metabolism to potentially reduce cancer growth, and this phase I trial aims to determine the maximally tolerated dose when given with chemoradiation or radiation therapy alone. The study also explores tumor control, progression, survival rates, and predictive biomarkers using imaging and blood tests. Participants receive papaverine intravenously or subcutaneously over 30 minutes alongside chemoradiation involving radiation therapy five times per week for 3 to 6 weeks. Chemotherapy drugs paclitaxel with carboplatin or pemetrexed with carboplatin are given intravenously on schedules during radiation. Patients with PD-L1 positive disease may receive durvalumab after chemoradiation if deemed appropriate. Imaging scans such as PETCT, CT, and brain MRI, as well as blood sample collections, are performed during screening and throughout the study. Participants are followed for up to 5 years after treatment, with visits scheduled frequently in the first 2 years to monitor tumor control, disease progression, survival, and changes in imaging and biomarkers. Assessments include blood oxygen level imaging BOLD MRI, tissue and blood biomarker analysis, and safety monitoring. The study measures the highest safe dose of papaverine combined with chemoradiation and tracks long-term outcomes to better understand treatment effects and patient responses.
CONDITIONS
Brief Title
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Research Team
T
The Ohio State University Comprehensive Cancer Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here